Neurology & Brain Disorders Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

The Synapse Project

This Phase 2 study from the University of Wisconsin, Madison explored a new brain imaging technique using UCB-J PET scans to better understand how Alzheimer’s disease progresses. By improving early and accurate tracking of brain changes, this method could help doctors diagnose Alzheimer’s sooner and monitor its development more closely. With 100 participants completing the study, these results offer promising insights for future care and research.

Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)

This Phase 3 trial led by Columbia University tested whether improving blood flow to the brain through a procedure called revascularization can help cognitive function in people who have narrowing of a major neck artery but no symptoms. The study enrolled 392 patients across the US and Canada and focused on those with early cognitive decline linked to blood flow problems. If successful, this approach could provide a new way to slow or reverse memory and thinking difficulties related to artery narrowing.

GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

This international study from West China Hospital looked at how a class of diabetes medicines called GLP-1 receptor agonists might affect Alzheimer’s disease in adults with type 2 diabetes or obesity. Analyzing data from over two million people, the study suggests these drugs could lower Alzheimer’s risk or slow its progression in this group. These findings may open new possibilities for preventing or managing Alzheimer’s in people with certain health conditions.

Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study

Cerecin’s Phase 3 trial is testing tricaprilin, an oral medication, in people with mild to moderate Alzheimer’s disease. The goal is to see if this treatment can improve memory and daily functioning. With plans to enroll up to 535 participants, this study could lead to a new treatment option that helps people live more independently for longer.

Internet-based Mind-Body Training for Brain Health

Ohio State University is running a study on an 8-week internet mindfulness program for adults aged 50 and older experiencing early memory or thinking concerns. This non-drug approach aims to improve brain health and reduce early symptoms that often precede Alzheimer’s disease. The program’s online format could make brain health support more accessible to many people at risk.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.